Skip to main content

Lung Cancer HELPLine 833-797-5800

LUNGevity.org

Patient Gateway

Lung Cancer HELPLine 833-797-5800

Patient Gateway

Video Library

You are about to leave the Patient Gateway

You’re one click away from learning about one of our most valued sponsors. Read about how they’re making a difference in patients’ lives.

ProceedCancel

  • Banner with title and photo

    Article

    May 14, 2024

    Safely Bring Yoga, Dietary Supplements, Exercise, and More into Your Lung Cancer Journey

    Read time: 2 minutes Integrative oncology adds holistic approaches—such as acupuncture, nutrition, exercise, and mindfulness—into a treatment plan. Research shows these...
    READ MORE about Safely Bring Yoga, Dietary Supplements, Exercise, and More into Your Lung Cancer Journey ›
  • Title of article with research-related photos

    Article

    April 25, 2024

    Highlights of AACR 2024: Where the Laboratory Meets the Patient

    Read time: 7 minutes It’s spring! The daffodils bloom, the days become longer, and I attend the annual meeting of the American Association for Cancer Research (AACR). For those of...
    READ MORE about Highlights of AACR 2024: Where the Laboratory Meets the Patient ›
  • Headline graphic

    Article

    April 12, 2024

    Chemo Shortage Didn’t Materialize ‘The Way We Initially Feared’

    This March, LUNGevity Foundation partnered with CURE for their “Speaking Out” video series, inviting Amy Moore, PhD, vice president of global engagement and patient partnerships at...
    READ MORE about Chemo Shortage Didn’t Materialize ‘The Way We Initially Feared’ ›
  • Title slide featuring Michelle Bolden

    Video

    March 28, 2024

    Caregivers: Planning the Self-Care Journey

    This webinar explains the phases of the caregiving cycle and offers tips and strategies for meeting the challenges of each phase. The discussion features Michelle Bolden, founder...
    READ MORE about Caregivers: Planning the Self-Care Journey ›
  • Title graphic showing panelists

    Video

    February 08, 2024

    Diving Deeper: Targeted Therapy, Radiation, and Immunotherapy

    Lung cancer experts from Johns Hopkins Kimmel Cancer Center dive into the how and why behind targeted therapy, immunotherapy, and radiation therapy. Touching on improvements to...
    READ MORE about Diving Deeper: Targeted Therapy, Radiation, and Immunotherapy ›
  • Photo of Marnie with the title

    Article

    January 09, 2024

    Finding Balance in Life and Treatment with Marnie Clark

    The symptoms that led Marnie Clark to her doctor were unusual. Her leg was feeling “weird,” but it was more of an annoyance than something she was concerned about. Then came an...
    READ MORE about Finding Balance in Life and Treatment with Marnie Clark ›
  • Title banner with a photo of Dr. Alex Bryant

    Article

    December 06, 2023

    Building a Computational Model to Optimize Patient Treatment

    Approximately 20%-35% of patients newly diagnosed with non-small cell lung cancer (NSCLC) will have locally advanced disease, sometimes referred to as stage III NSCLC. The...
    READ MORE about Building a Computational Model to Optimize Patient Treatment ›
  • Clinical Trial Phases

    Video

    November 30, 2023

    Clinical Trial Phases

    The four phases of lung cancer clinical trials each serve a different and important purpose. From testing the safety of a new treatment to its effectiveness and long-term outcomes...
    READ MORE about Clinical Trial Phases ›
  • Graphic with man smiling and holding a phone

    Article

    November 29, 2023

    Helpful Apps for People Living with Cancer

    As mobile apps become more ingrained in our lives, it’s natural to look for ones that can help manage a cancer diagnosis. As for which app to choose, it really comes down to what...
    READ MORE about Helpful Apps for People Living with Cancer ›
  • Graphic showing FDA approval alert

    Article

    November 18, 2023

    Repotrectinib is Now FDA-Approved to Treat Patients with ROS1-positive NSCLC

    On November 15, 2023, the US Food and Drug Administration (FDA) announced the approval of repotrectinib to treat patients with locally advanced or metastatic ROS1-positive non...
    READ MORE about Repotrectinib is Now FDA-Approved to Treat Patients with ROS1-positive NSCLC ›
  • Banner graphic with photos of awardees

    Article

    November 16, 2023

    Drs. Susumu Kobayashi and Alexandre Reuben Announced as Recipients of EGFR Resisters/LUNGevity Research Award

    LUNGevity Foundation is thrilled to announce the recipients of the EGFR Resisters/LUNGevity Research Award for EGFR-Positive Lung Cancer. EGFR Resisters, a vibrant patient-led...
    READ MORE about Drs. Susumu Kobayashi and Alexandre Reuben Announced as Recipients of EGFR Resisters/LUNGevity Research Award ›
  • Banner graphic with photo of each grant recipient

    Article

    November 16, 2023

    LUNGevity Announces $1.2M in Lung Cancer Workforce Development Research Awards

    LUNGevity Foundation is proud to announce the recipients of four awards to bolster the lung cancer research workforce— the Career Development Award, the VA Research Scholar Award...
    READ MORE about LUNGevity Announces $1.2M in Lung Cancer Workforce Development Research Awards ›

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 1
  • Page 2
  • Page 3
  • Current page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Next page Next ›
  • Last page Last »
SHARE

The Patient Gateways are a project of LUNGevity Foundation, an organization transforming how people are diagnosed and live with lung cancer. Learn more here.

Privacy policy | Contact us

 

This website is not intended to, and does not, provide medical advice, professional diagnosis, opinion, treatment, or services. Medical information provided on this site is for informational and educational purposes only. After reading content from this website, you are encouraged to review the information carefully with your physician.

 

Copyright © 2025 LUNGevity Foundation. All rights reserved.